Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …

SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed.
Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions
of infections and hundreds of thousands of deaths globally. There are no widely available …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical
interventions against COVID-19 disease. However, their common genetic and biologic …